Menoufia Medical Journal

REVIEW ARTICLE
Year
: 2020  |  Volume : 33  |  Issue : 1  |  Page : 1--4

Evidence base for cervical cancer screening and prevention among average-risk women in family practice


Hala M Shaheen1, Samah M. A El Galil Ebied2 
1 Department of Family Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Family Medicine at Ministry of Health, Barheem Health Unit, Menoufia, Egypt

Correspondence Address:
Samah M. A El Galil Ebied
Menouf City, Elmonfiya Governorate
Egypt

Objective The aim was to perform a systematic review to identify and summarize evidence base for cervical cancer screening in asymptomatic women who were aged 21 years or older attending family practice. Materials and methods Medline, articles in Medscape, American Academy of Family Physicians, and PubMed were searched. Data were collected from April 1, 2015 till August 1, 2015. The initial search presented 150 articles. The researches which met the inclusion criteria were 24 articles. The articles included screening modalities for cervical cancer in asymptomatic women who were aged 21 years or older attending family practice. If the studies did not fulfill the inclusion criteria, they were excluded. Study quality assessment included whether ethical approval was gained, eligibility criteria specified, appropriate controls, adequate information, and assessment measures defined. Comparisons were made by a structured review with the results tabulated. Recent findings Total 24 potentially relevant publications were included. All relevant studies stated that screening should start at 21 years, mean age (±3) till 65 years (grade A recommendation). Regarding the screening test, all studies recommended cervical cytology (pap test) with a 3-year screening interval (grade A recommendation). All studies recommended screening with a combination of cytology and human papillomavirus (HPV)(co-testing) every 5 years for women in the age group of 30–65 years who want to lengthen the screening interval (grade A recommendation). All studies recommended against using HPV testing as a primary screening method or under 30 years. Regarding vaccination two studies suggest HPV vaccine for cervical cancer prevention. Conclusion Screening for cervical cancer is recommended from 21 to 65 years old with cytology (Pap) test with a 3-year screening interval. Women 30 years and older who want to lengthen the screening interval are screened by cytology plus HPV (co-testing) every 5 years.


How to cite this article:
Shaheen HM, El Galil Ebied SM. Evidence base for cervical cancer screening and prevention among average-risk women in family practice.Menoufia Med J 2020;33:1-4


How to cite this URL:
Shaheen HM, El Galil Ebied SM. Evidence base for cervical cancer screening and prevention among average-risk women in family practice. Menoufia Med J [serial online] 2020 [cited 2020 Nov 24 ];33:1-4
Available from: http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2020;volume=33;issue=1;spage=1;epage=4;aulast=Shaheen;type=0